About the Coleman Institute
The mission of the Coleman Institute for Cognitive Disabilities is to catalyze and integrate advances in science, engineering, and technology to promote the quality of life and independent living of people with cognitive disabilities. Over 29 million people in the U.S. alone are affected by impaired cognitive function such as intellectual disabilities, brain injury, Alzheimer's disease, stroke, and serious, persistent mental illness. An estimated 350,000 persons in Colorado have cognitive disabilities.
The Institute is actively engaged in supporting research, development, dissemination, and education in cognitive disabilities on all campuses of the University of Colorado: in Boulder , Colorado Springs , Denver , and at the Anschutz Medical Campus in Aurora. We are committed to providing scientific, technological, and public policy leadership to strengthen the voice of persons with cognitive disabilities and their families in our society.
The Coleman Institute for Cognitive Disabilities was established in 2001 by the Regents of the University of Colorado. A private endowment and sustained annual contributions by our founding donors, William T. and Claudia L. Coleman, support the Institute's activities through the Coleman Colorado Foundation (CCF), which was established to receive gifts from the donors. The CCF is a 501 (c) (3) public charity classified as a 509 (a) (3) supporting organization to the University of Colorado (CU) to support the Coleman Institute.
The Executive Director of the Institute is David Braddock, PhD, who is also Senior Associate Vice President of the University of Colorado system and holds the Coleman-Turner Chair in the School of Medicine, Department of Psychiatry at CU's Anschutz Medical Campus. The Associate Director for Administration is Enid Ablowitz; The Associate Director for Research is Emily Shea Tanis, Ph.D. who is also a Senior Instructor in the Department of Psychiatry at the Anschutz Medical Campus.